Prostate Cancer Clinical Trial
Official title:
Phase II Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising PSA on Hormone Therapy
The primary objective of this study is to evaluate the effect of erlotinib on the PSA
response rate in patients with non-metastatic prostate cancer and a rising PSA on androgen
deprivation therapy.
The secondary objectives are to evaluate the effect of erlotinib on the duration of PSA
response, to evaluate the effect on the time to PSA progression, to evaluate the toxicity of
erlotinib in this patient population, and lastly, to correlate the effect of erlotinib with
various epidermal growth factor receptor (EGFR)-related proteins using baseline
immunohistochemical (IHC) studies on tissue blocks and peripheral blood mononuclear cells.
Patients with prostate cancer who are treated with surgery or radiation often develop
recurrence of their cancer which is manifest only by a rising PSA (Prostate Specific
Antigen) level. Many of these patients are treated with hormone therapy. After a fall in the
PSA, these patients eventually display evidence of tumor progression clearly demonstrated by
another rise in PSA level while receiving hormone therapy. Evaluation for evidence of tumor
spread is usually negative. There is currently no effective therapy approved for use in
these patients.
The drug erlotinib works by blocking the activity of a protein called Epidermal Growth
Factor Receptor (EGFR), which is located on the surface of many prostate cancer cells.
Blockage of this protein has been shown to inhibit the growth of prostate tumor cells in a
laboratory setting and in animal experiments. Erlotinib has been given to patients with
other types of cancers. A recently completed study showed that erlotinib improved the
survival of patients with advanced lung cancer who failed standard chemotherapy.
There is currently no effective therapy approved for use in patients with this condition.
The purpose of this study is to evaluate the effectiveness and side effects of the drug
erlotinib in patients with this condition. Erlotinib is an investigational drug that has not
yet been approved by the Federal Drug Administration (FDA) for use in prostate cancer, but
has been approved for use in lung cancer.
As previously stated: The primary objective of this study is to evaluate the effect of
erlotinib on the PSA response rate in patients with non-metastatic prostate cancer and a
rising PSA on androgen deprivation therapy.
Secondary objectives are to evaluate the effect of erlotinib on the duration of PSA
response, to evaluate the effect on the time to PSA progression, to evaluate the toxicity of
erlotinib in this patient population, and lastly, to correlate the effect of erlotinib with
various EGFR-related proteins using baseline immunohistochemical (IHC) studies on tissue
blocks and peripheral blood mononuclear cells.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
| Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
| Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
| Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
| Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
| Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |